LM-101 / Sino Biopharm - LARVOL DELTA

LM101-01-103: A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - P1/2 | N=139 | Recruiting | Sponsor: LaNova Medicines Limited | Suspended ➔ Recruiting | Trial completion date: Aug 2025 ➔ Jan 2028 | Trial primary completion date: Dec 2024 ➔ Jan 2027

Enrollment open • Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Primary analysis of a phase 1/2 study of LM-101: An anti-SIRPα antibody as a single agent in patients with advanced malignancies. (ASCO 2024) - P1/2 | "LM-101 monotherapy showed excellent safety profile and promising anti-tumor activity in patients with advanced malignancies. Further investigation of LM-101 as a single agent and in combination with other anti-tumor agents are ongoing."

Clinical • Metastases • P1/2 data • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor • SIRPA

A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - P1/2 | N=145 | Suspended | Sponsor: LaNova Medicines Limited

Combination therapy • Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - P1/2 | N=145 | Suspended | Sponsor: LaNova Medicines Limited | Recruiting ➔ Suspended

Combination therapy • Metastases • Trial suspension • Oncology • Solid Tumor

A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - P1/2 | N=145 | Recruiting | Sponsor: LaNova Medicines Limited | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • IO biomarker • Metastases • Oncology • Solid Tumor • CD163 • CD68 • CD8 • PD-L1

A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - P1/2 | N=145 | Not yet recruiting | Sponsor: LaNova Medicines Limited

Combination therapy • IO biomarker • New P1/2 trial • Oncology • Solid Tumor • CD163 • CD68 • CD8 • PD-L1